Interleukin-10 Gene Promoter and NFKB1 Promoter Insertion/Deletion Polymorphisms in Systemic Sclerosis

Scandinavian Journal of Immunology

Volumn 77, Issue 2, 2013, Pages 162-168

  Salim, P H ^a   Jobim, M ^b   Bredemeier, M ^b   Chies, J A B ^a   Brenol, J C T ^b   Jobim, L F ^a   Xavier, R M ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10;

ALLELE; ARTICLE; BONE MARROW; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA POLYMORPHISM; DOPPLER ECHOCARDIOGRAPHY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEROLOGY; SYSTEMIC SCLEROSIS;

ALLELES; CASE-CONTROL STUDIES; EPISTASIS, GENETIC; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; INTERLEUKIN-10; NF-KAPPA B P50 SUBUNIT; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SCLERODERMA, SYSTEMIC;

EID: 84872838015     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12020     Document Type: Article

References (39)

1. Mayes MD, Trojanowska M. Genetic factors in systemic sclerosis. Arthritis Res Ther 2007;9 (Suppl 2):S5.
2. Oliveira CC, Teodoro WR, Velosa APP, Yoshinari NH. Autoimmunity and collagen V. Rev Bras Reumatol 2006;46:194-8.
3. Ghosh AK. Factors involved in the regulation of type 1 collagen gene expression: implication in fibrosis. Exp Biol Med 2002;227:301-14.
4. Kim JM, Brannan CI, Copeland NG, Jenkins NA, Khan TA, Moore KW. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol 1992;148:3618-23.
5. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
6. Timmann C, Fuchs S, Thoma C et al. Promoter haplotypes of the interleukin-10 gene influence proliferation of peripheral blood cells in response to helminth antigen. Genes Immun 2004;5:256-60.
7. Ates O, Müsellim B, Ongen G, Topal-Sarikaya A. Association between 'interleukin' 10 gene (IL10) polymorphisms and systemic sclerosis with interstitial lung involvement. Rheumatol Int 2008;28:1123-6.
8. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. Analysis of the 5′ flanking region of the interleukin 10 gene in patients with systemic sclerosis. Rheumatology 2003;42:1295-8.
9. Beretta L, Cappiello F, Barili M et al. Proximal interleukin-10 gene polymorphisms in Italian patients with systemic sclerosis. Tissue Antigens 2007;69:305-12.
10. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203-8.
11. Karban AS, Okazaki T, Panhuysen CI et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35-45.
12. Le Beau MM, Ito C, Cogswell P et al. Chromosomal localization of the genes encoding the p50/p105 subunits of NF-kappa B (NFKB2) and the I kappa B/MAD-3 (NFKBI) inhibitor of NF-kappa B to 4q24 and 14q13, respectively. Genomics 1992;14:529-31.
13. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995;38:1762-70.
14. Orozco G, Sanchez E, Collado MD et al. Analysis of the functional NFKB1 promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2005;65:183-6.
15. Kim TH, Stone MA, Rahman P et al. Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea. J Rheumatol 2005;32:1907-10.
16. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Committee. Arthritis Rheum 1980;23:581-90.
17. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
18. Bredemeier M, Xavier RM, Capobianco KG et al. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol 2004;31:286-94.
19. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
21. Denize Atan J, Turner J, Kilmartin V et al. Cytokine Gene Polymorphism in Sympathetic Ophthalmia. Invest Ophthalmol Vis Sci 2005;46:4245-50.
22. Lewander A, Butchi AK, Gao J et al. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol 2007;42:1332-8.
23. Abramson JH, Gahlinger PM. Computer Programs for Epidemiologists: PEPI v.4.0. Salt Lake City, UT: Sagebrush Press, 2001.
24. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10 transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol 1998;6:193-7.
25. Yilmaz V, Yentur SP, Saruhan-Direskeneli G. IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine 2005;30:188-94.
26. Peng WJ, Wang BX, Pan HF et al. Association of the interleukin-10 1082G/A, 819C/T and 3575T/A gene polymorphisms with systemic sclerosis: a meta-analysis. Mol Biol Rep 2012;39:6851-5.
27. Eskdale J, Wordsworth P, Bowman S et al. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 1997;49:635-9.
28. Gao M, Wang CH, Sima X, Han XM. NFKB1 -94 Insertion/Deletion ATTG Polymorphism Contributes to Risk of Systemic Lupus Erythematosus. DNA Cell Biol 2012;31:611-5.
29. Kessel A, Rosner I, Rozenbaum M et al. Increased CD8C T Cell Apoptosis in Scleroderma Is Associated With Low Levels of NF-kB. J Clin Immunol 2004;24:30-6.
30. Chen F, Castranova V, Shi X et al. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7-17.
31. Sha WC, Liou HC, Tuomanen EI et al. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 1995;80:321-30.
32. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007;22:1387-98.
33. Martimath;nez A, Sanchez E, Valdivia A et al. Epistatic interaction between FCRL3 and NFkappaB1 genes in Spanish patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1188-91.
34. Zou YF, Wang F, Feng XL et al. Association of NFKB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. Tissue Antigens 2011;77:9-17.
35. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995;270:9558-63.
36. Yamamoto T, Eckers B, Kreig T. Effect of interleukin 10 on the gene expression of type 1 collagen, fibronectin and decorin in human skin fibroblasts: differential regulation by transforming growth factor and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 2001;281:200-5.
37. Ten RM, Paya CV, Israel N et al. The characterization of the promoter of the gene encoding the p50 subunit of NF-κB indicates that it participates in its own regulation. EMBO J 1992;11:195-203.
38. Zhang G, Ghosh S. Toll-like receptor-mediated NF-κB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001;107:13-9.
39. Girardin SE, Hugot JP, Sansonetti PJ. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol 2003;24:652-8.